Minerva Neurosciences Inc. (NASDAQ: NERV) announced it has secured up to $200 million in financing to advance its roluperidone drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE